-
-
-
-
-
-
-
TransCode Therapeutics acquires Polynoma for $25 million from CK Life Sciences
-
-
-
-
-
-
-
TransCode Therapeutics (RNAZ) Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Trial
-
-
-
-
-
-
-
TransCode Therapeutics (RNAZ) Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
-
-
-
-
444,453 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

